Web Exclusives
Web Exclusives — March 17, 2020
For many patients with chronic lymphocytic leukemia (CLL), treatment is personalized. This means that oncologists tailor their medication choices based on the patient’s unique CLL characteristics and medical status. Read More ›
Web Exclusives — March 17, 2020
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions. Read More ›
Web Exclusives — March 17, 2020
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients. Read More ›
Web Exclusives — March 1, 2020
Machines that use artificial intelligence—such as Siri and Alexa—have become part of our everyday lives. Could this technology help in the fight against breast cancer? See how human doctors stacked up against machines in one study. Read More ›
Web Exclusives — February 12, 2020
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials. Read More ›
Web Exclusives — February 12, 2020
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing? Read More ›
Web Exclusives — February 12, 2020
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease. Read More ›
Web Exclusives — February 12, 2020
In the era of targeted treatments for CLL, should patients with early-stage disease be placed on therapy before they experience symptoms? Doctors continue to debate this question while waiting for clinical trial data to evolve. Read More ›
Web Exclusives — February 12, 2020
Chronic lymphocytic leukemia (CLL) is a type of blood cancer. Some patients with CLL may not need treatment right away, whereas others require more urgent attention. How do cancer specialists decide when to start patients on therapy? Read More ›
Web Exclusives — January 15, 2020
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes can affect how much patients must pay out of pocket for their medications, including certain cancer drugs. Read More ›